Full text is available at the source.
Exploring synergistic therapy for metabolic dysfunction-associated steatotic liver disease
Combined treatments for fatty liver disease linked to metabolism problems
AI simplified
Page updated
Abstract
The FDA has approved resmetirom, a selective thyroid hormone receptor-β agonist, for managing metabolic-associated steatotic liver disease (MASLD).
- Obesity is linked to an increase in MASLD, contributing to a significant global health burden.
- Current treatments focus on lifestyle changes, weight loss, and pharmacological agents like GLP-1 receptor agonists.
- Resmetirom and GLP-1 receptor agonists have shown individual effectiveness in treating MASLD and related metabolic disorders.
- The potential benefits of combining resmetirom with GLP-1 receptor agonists for MASLD management have not yet been investigated.
AI simplified